Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease (Q33895677)

29 July 2017

title

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

29 July 2017

main subject

0 references

1 reference

1 reference

4

Targan SR

1 reference

29 July 2017

Dubinsky MC

1

1 reference

29 July 2017

Lamothe S

2

1 reference

29 July 2017

Yang HY

3

1 reference

29 July 2017

Sinnett D

5

1 reference

29 July 2017

Théorêt Y

6

1 reference

29 July 2017

Seidman EG

7

1 reference

29 July 2017

publication date

1 April 2000

1 reference

29 July 2017

language of work or name

0 references

1 reference

29 July 2017

volume

118

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

705-713

1 reference

Controlled trial of azathioprine in Crohn's disease

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

A controlled double blind study of azathioprine in the management of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

The clinical pharmacology of 6-mercaptopurine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Cortisone in ulcerative colitis; final report on a therapeutic trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Clinical classification of perianal Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Nuclear DNA diversity in worldwide distributed human populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6‐mercaptopurine and azathioprine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

Classification of inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970140-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0016-5085(00)70140-5

1 reference

29 July 2017

1 reference